143 related articles for article (PubMed ID: 16751163)
1. Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes.
Taki H; Maki T; Iso T; Iwamoto K; Kajiura T
Adv Ther; 2006; 23(2):307-24. PubMed ID: 16751163
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing surveillance study of nateglinide in Japan.
Taki H; Maki T; Iso T; Iwamoto K; Kajiura T
Adv Ther; 2005; 22(5):513-26. PubMed ID: 16418160
[TBL] [Abstract][Full Text] [Related]
3. Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes.
Taki H; Maki T; Iso T; Tanabe S; Kajiura T
Adv Ther; 2005; 22(6):621-35. PubMed ID: 16510379
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Li YX; Ding GX; Li QF; Chen L; Hu GL; Ji QH; Wang SJ; Guo Y; Luo R; Hou WK; Wang PN; Zhang NY; Zhang YP; Wang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):211-3. PubMed ID: 18505128
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
6. Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes.
Onishi Y; Fujisawa T; Sakaguchi K; Maeda M
Adv Ther; 2006; 23(4):549-55. PubMed ID: 17050498
[TBL] [Abstract][Full Text] [Related]
7. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Chandrasekharan S; Rao PP; Jayaram S; Jain SD; Ganesan R; Desai A
J Indian Med Assoc; 2002 Jul; 100(7):467-8. PubMed ID: 12674176
[TBL] [Abstract][Full Text] [Related]
9. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
González-Clemente JM;
Eur J Clin Invest; 2008 Mar; 38(3):174-9. PubMed ID: 18257780
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
13. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Yang JK; Wang L;
Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
15. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
16. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
17. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
18. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
